Real-world outcomes of subsequent treatment strategies after durvalumab consolidation in stage III unresectable non-small cell lung cancer
Platinum-based chemotherapy was the predominant treatment after durvalumab consolidation. Immunotherapy rechallenge was associated with the best survival outcome in selected cases, warranting further investigation.
Authors
- Maria E. Pagano (ORCID: https://orcid.org/0000-0003-4406-8894)
- Francesco Passiglia (ORCID: https://orcid.org/0000-0002-0244-5738)
- Veronica Crespi
- Gabriele Minuti (ORCID: https://orcid.org/0000-0003-2363-0446)
- Carlo Greco
- Alessandro Russo (ORCID: https://orcid.org/0000-0002-3365-1972)
- Sara Pilotto (ORCID: https://orcid.org/0000-0003-2229-4874)
- Stefania Gori (ORCID: https://orcid.org/0000-0001-6320-405X)
- Roberta Buosi
- Francesco Grossi (ORCID: https://orcid.org/0000-0001-8412-3136)
- Marco Donatello Delcuratolo (ORCID: https://orcid.org/0000-0003-3151-9166)
- Giulio Metro (ORCID: https://orcid.org/0000-0002-4978-9212)
- Alessandra Bulotta (ORCID: https://orcid.org/0000-0002-6984-4813)
- Emanuela Olmetto
- Alessandro Morabito (ORCID: https://orcid.org/0000-0002-1319-9608)
- Diego Cortinovis (ORCID: https://orcid.org/0000-0001-7611-7369)
- Michele Montrone
- Elisa Roca (ORCID: https://orcid.org/0000-0001-7625-7708)
- Giacomo Pelizzari (ORCID: https://orcid.org/0000-0003-1224-9906)
- Alessandro Leonetti (ORCID: https://orcid.org/0000-0001-5415-6703)
- Daniele Pignataro (ORCID: https://orcid.org/0000-0001-7561-622X)
- Claudio Sini
- Carlo Genova (ORCID: https://orcid.org/0000-0003-3690-8582)
- Alessandro Del Conte (ORCID: https://orcid.org/0000-0003-1763-0335)
- Diana Giannarelli (ORCID: https://orcid.org/0000-0002-6085-1195)
- Giulia Pasello (ORCID: https://orcid.org/0000-0002-8741-6038)
- Silvia Novello
Institutions
- University of Insubria (IT)
- University of Verona (IT)
- University of Parma (IT)
- Agostino Gemelli University Polyclinic (IT)
- Ospedale Sacro Cuore Don Calabria (IT)
- Casa di Cura Villa Garda (IT)
- ATS Sardegna (Italy) (IT)
- Azienda Sanitaria Locale di Asti (IT)
- Azienda Ospedaliero-Universitaria Careggi (IT)
- Ospedale Santa Maria (IT)
- Centro di Riferimento Oncologico (IT)
- IRCCS Ospedale San Raffaele (IT)
- Istituti di Ricovero e Cura a Carattere Scientifico (IT)
- Ospedale San Luigi Gonzaga (IT)
- University of Turin (IT)
Publication Details
- Journal
- Lung Cancer
- Published
- 2025-05-03
- DOI
- https://doi.org/10.1016/j.lungcan.2025.108576
- Citations
- 3
- Primary Topic
- Lung Cancer Diagnosis and Treatment
- Type
- article
- Field-Weighted Citation Impact
- 4.56
Funders
- Amgen
- Eli Lilly and Company
- Pfizer
- AstraZeneca
- Sanofi
- Regeneron Pharmaceuticals
- Daiichi Sankyo Europe